A Phase 1 Trial of the Safety, Tolerability, and Biological Effects of Intravenous Enadenotucirev (EnAd), a Novel Oncolytic Virus, in Combination with Chemoradiotherapy in Locally Advanced Rectal Cancer (CEDAR).

enadenotucirev (ColoAd1) - Akamis Bio, BMS

capecitabine - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/37785164

A OOMS; K Fisher; L Seymour; M A Hawkins; M Qiao; R Adams; R Brown; R Muirhead; S M O'Cathail; S Rao; T Lille; T S Maughan

Oct 3, 2023